Net margin is calculated as Net Income divided by its Revenue. GNI Group's Net Income for the
three
months ended in Mar. 2026 was 円-2,127 Mil. GNI Group's Revenue for the
three
months ended in Mar. 2026 was 円5,526 Mil. Therefore, GNI Group's net margin for the quarter that ended in Mar. 2026 was -38.49%.
The historical rank and industry rank for GNI Group's Net Margin % or its related term are showing as below:
TSE:2160'
s Net Margin % Range Over the Past 10 Years
Min: -39.26 Med: 2.34 Max: 31.12
Current: -21.6
TSE:2160's Net Margin % is ranked better than 62.16% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs TSE:2160: -21.60
GNI Group (TSE:2160) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
GNI Group Net Margin % Related Terms
GNI Group Net Margin % Historical Data
* Premium members only.
The historical data trend for GNI Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2160 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, GNI Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GNI Group Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GNI Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where GNI Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNI Group (TSE:2160) has a Net Margin % of -38.49% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on GNI Group and its competitors. According to the industry distribution chart, GNI Group ranks #358 out of 946 companies in the Biotechnology industry, placing it in the top 37.8%.
Is GNI Group's Net Margin % too high?
GNI Group's current Net Margin % is -38.49%. Based on the distribution chart, GNI Group ranks #358 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GNI Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GNI Group's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, GNI Group ranks #358 out of 946 companies for Net Margin %. This puts GNI Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on GNI Group and its competitors. GNI Group's current Net Margin % is -38.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GNI Group stock overvalued right now?
Based on GuruFocus' analysis, GNI Group (TSE:2160) is currently considered Fairly Valued. The stock's GF Value™ is 円2,777.99, compared to a current price of 円2,517.00 — trading 9.4% below its estimated fair value. The current Net Margin % is -38.49%. GNI Group's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For GNI Group (TSE:2160), the current Net Margin % is -38.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GNI Group (TSE:2160) Overvalued in 2026?
Based on GuruFocus' analysis, GNI Group stock appears to be undervalued.
The current stock price of 円2,517.00 is trading 9.4% below its estimated GF Value™ of 円2,777.99.
GuruFocus considers GNI Group to be Fairly Valued.
Key valuation signals for TSE:2160:
Net Margin %: -38.49%
GF Value™: 円2,777.99 vs. price of 円2,517.00 (9.4% below fair value)
No single metric tells the full story. See the TSE:2160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
83GF Score
Get the complete analysis for TSE:2160
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2160 has been successfully added to your 
